End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
247.5 TWD | +0.41% | -2.94% | -10.65% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With an enterprise value anticipated at 4.31 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.65% | 645M | - | ||
+22.39% | 43.96B | B | ||
-0.30% | 18.75B | B- | ||
-20.50% | 2.22B | D+ | ||
+25.60% | 2.11B | C+ | ||
+19.17% | 1.13B | - | ||
-38.32% | 716M | - | ||
-44.53% | 632M | B- | ||
+57.22% | 606M | - | - | |
+17.51% | 494M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 3218 Stock
- Ratings Universal Vision Biotechnology Co., Ltd.